EMILY HIMEBAUGH: Open Payments
NPI 1285936617 · WEST JORDAN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,519 in 129 payments from 21 companies in 2025. Trend: 2023 $2,653 · 2024 $2,855 · 2025 $2,519
Food & beverage: $2,519
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $566 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $351 |
| Janssen Biotech, Inc. | 17 | $268 |
| Ardelyx, Inc. | 12 | $217 |
| Madrigal Pharmaceuticals | 5 | $211 |
| Aimmune Therapeutics, Inc. | 11 | $170 |
| Gilead Sciences, Inc. | 4 | $112 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $110 |
| PFIZER INC. | 4 | $81 |
| GENZYME CORPORATION | 4 | $77 |
Products named: ENTYVIO, TREMFYA, IBSRELA, REZDIFFRA, RINVOQ, SKYRIZI, ZENPEP, DUPIXENT.
Industry payments across UT — which companies pay providers there.
